New drug cocktail aims to tackle tough sarcomas in young patients
NCT ID NCT06709495
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called PEEL-224 combined with two standard chemotherapy drugs (vincristine and temozolomide) in adolescents and young adults whose sarcomas have returned or not responded to treatment. The trial has two phases: first, finding the safest dose, then checking how well the combination shrinks tumors. About 63 participants with Ewing sarcoma, desmoplastic small round cell tumors, or other sarcomas will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PEEL-224 (a topoisomerase 1 inhibitor) combined with vincristine and temozolomide
What this could lead to
If successful, this combination could offer a new treatment option for young people with sarcomas that have come back or not responded to standard therapy.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are uncertain. The drugs may cause serious side effects, and the combination might not shrink tumors effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Boston Children's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Brigham and Women's Hospital
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact